European Journal of Cancer
Volume 38 , Pages 21-25 , February 2002

Future treatment options with capecitabine in solid tumours

  • H Wilke

      Affiliations

    • Corresponding Author InformationTel.: +49-201-174-1250; fax: +49-201-1740-1255

Received 25 June 2001 ,Revised 26 November 2001 ,Accepted 29 November 2001.

References 

  1. Blum JL, Jones SE, Buzdar AU, et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999;17:485–493
  2. Blum JL, Dieras V, LoRusso PM, et al.  Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer. 2001;92:1759–1768
  3. Van Cutsem E, Twelves C, Cassidy J, et al.  Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic Regimen) in patients with metastatic colorectal cancer (results of a large phase III study). J. Clin. Oncol. 2001;19:4097–4106
  4. Hoff M, Ansari R, Batist G, et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer (results of a randomized phase III study). J. Clin. Oncol. 2001;19:2282–2292
  5. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997;15:110–115
  6. Borner M, Schöffski P, de Wit R, et al. A randomised crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 2000, 19, 191 (abstr).
  7. Kitazono M, Takebayashi Y, Ishitsuka K, et al.  Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun. 1998;253:797–803
  8. Danenberg K, Metzger R, Salonga D, et al. Thymidine phosphorylase expression in colorectal tumours together with that of thymidylate synthase predict tumor response to 5-fluorouracil. Proc Am Assoc Cancer Res Annu Meet 1997, 38, 614-615 (abstr).
  9. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685–690
  10. Ishikawa T, Utoh M, Sawada N, et al.  Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 1998;55:1091–1097
  11. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res. 1998;4:1013–1019
  12. Endo M, Shinbori N, Fukase Y, et al.  Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer. 1999;83:127–134
  13. Pronk LC, Vasey P, Sparreboom A, et al.  A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br. J. Cancer. 2000;83:22–29
  14. Dı́az-Rubio E, Evans J, Tabernero J, et al. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol (in press).
  15. Zeuli M, Di Costanzo F, Sdrobolino A, et al. A dose-finding study of capecitabine in combination with oxaliplatin (L-OHP) in advanced colorectal cancer (CRC). Ann Oncol 2000, 11 (Suppl. 2), 76 (abstr).
  16. Thomas R, Quinn M, Wilson R, et al. A phase I trial of capecitabine (CAPE) & oxaliplatin (OHP). Proc Am Soc Clin Oncol 2001, 20, 133a (abstr).
  17. Bleiberg H. Role of chemotherapy for advanced colorectal cancer (new opportunities). Semin. Oncol. 1996;23(Suppl. 3):42–50
  18. Mitry E, Ducreux M, Rougier P. (Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials). Bull Cancer 1998, Spec No. 38–42.
  19. Van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil (a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group). Semin. Oncol. 1999;26(Suppl. 5):13–20
  20. Douillard JY, Cunningham D, Roth AD, et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer (a multicentre randomised trial). Lancet. 2000;355:1041–1047
  21. Vanhoefer U, Harstrick A, Köhne C, et al.  Phase I study of a weekly schedule of irinotecan, high-dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J. Clin. Oncol. 1999;17:907–913
  22. Schleucher N, Tewes M, Achterrath J, et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001, 20, 141a (abstr).
  23. Cassata A, Stani SC, Alù M, et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first-line chemotherapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001, 20, 144a (abstr).
  24. O'Connell MJ, Martenson JA, Weiand HS, et al.  Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiotherapy after curative surgery. N. Engl. J. Med. 1994;331:502–507
  25. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. 1999;5:2948–2953
  26. Dunst J, Reese T, Frings S. Phase I study of capecitabine combined with simultaneous radiotherapy in rectal cancer. Proc Am Soc Clin Oncol 2001, 20, 149a (abstr).
  27. Miwa M, Ura M, Nishida M, et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 1998;34:1274–1281

PII: S0959-8049(01)00417-8

European Journal of Cancer
Volume 38 , Pages 21-25 , February 2002

Article Tools

* Image Usage & Resolution